[go: up one dir, main page]

WO2008021483A3 - Prognostic and diagnostic method for disease therapy - Google Patents

Prognostic and diagnostic method for disease therapy Download PDF

Info

Publication number
WO2008021483A3
WO2008021483A3 PCT/US2007/018233 US2007018233W WO2008021483A3 WO 2008021483 A3 WO2008021483 A3 WO 2008021483A3 US 2007018233 W US2007018233 W US 2007018233W WO 2008021483 A3 WO2008021483 A3 WO 2008021483A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapy
markers
pathway
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/018233
Other languages
French (fr)
Other versions
WO2008021483A2 (en
Inventor
Gennadi V Glinksy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ordway Research Institute Inc
Original Assignee
Ordway Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/732,442 external-priority patent/US7890267B2/en
Application filed by Ordway Research Institute Inc filed Critical Ordway Research Institute Inc
Priority to EP07836975A priority Critical patent/EP2059615A2/en
Priority to CA002660857A priority patent/CA2660857A1/en
Publication of WO2008021483A2 publication Critical patent/WO2008021483A2/en
Anticipated expiration legal-status Critical
Publication of WO2008021483A3 publication Critical patent/WO2008021483A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancertherapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the 'sternness' pathway. The markers can be mRNA, microRNA, DNA, or protein.
PCT/US2007/018233 2006-08-17 2007-08-17 Prognostic and diagnostic method for disease therapy Ceased WO2008021483A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07836975A EP2059615A2 (en) 2006-08-17 2007-08-17 Prognostic and diagnostic method for disease therapy
CA002660857A CA2660857A1 (en) 2006-08-17 2007-08-17 Prognostic and diagnostic method for disease therapy

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US82270506P 2006-08-17 2006-08-17
US60/822,705 2006-08-17
US82357706P 2006-08-25 2006-08-25
US60/823,577 2006-08-25
US87506106P 2006-12-15 2006-12-15
US60/875,061 2006-12-15
USPCT/US2007/008088 2007-04-02
US11/732,442 US7890267B2 (en) 2006-03-31 2007-04-02 Prognostic and diagnostic method for cancer therapy
US11/732,442 2007-04-02
PCT/US2007/008088 WO2007114896A2 (en) 2006-03-31 2007-04-02 Prognostic and diagnostic method for cancer therapy
US92234007P 2007-04-05 2007-04-05
US60/922,340 2007-04-05

Publications (2)

Publication Number Publication Date
WO2008021483A2 WO2008021483A2 (en) 2008-02-21
WO2008021483A3 true WO2008021483A3 (en) 2009-03-26

Family

ID=56291006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018233 Ceased WO2008021483A2 (en) 2006-08-17 2007-08-17 Prognostic and diagnostic method for disease therapy

Country Status (3)

Country Link
EP (1) EP2059615A2 (en)
CA (1) CA2660857A1 (en)
WO (1) WO2008021483A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648021A1 (en) * 2006-03-31 2007-10-11 Ordway Research Institute, Inc. Prognostic and diagnostic method for cancer therapy
EP2283118A4 (en) 2008-05-06 2012-11-21 Agency Science Tech & Res METHOD FOR REALIZING THE DIFFERENTIATION OF A CELL
CN101792793B (en) * 2009-10-26 2012-05-23 中南大学 Application of miR-182 as glioma-generating molecular marker and detection kit thereof
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012135651A1 (en) 2011-03-31 2012-10-04 The Procter & Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
WO2013003583A2 (en) * 2011-06-29 2013-01-03 Duke University Somatic mutations in atrx in brain cancer
EP2751287A1 (en) 2011-10-07 2014-07-09 Université Montpellier 2, Sciences et Techniques Prognosis for glioma
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US9615269B2 (en) 2014-10-02 2017-04-04 At&T Intellectual Property I, L.P. Method and apparatus that provides fault tolerance in a communication network
EP3674421A1 (en) * 2018-12-28 2020-07-01 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Methods for the prognosis of prostate cancer
CN115116550A (en) * 2022-06-08 2022-09-27 中国科学院苏州生物医学工程技术研究所 Method for creating disease prognosis model, method for predicting disease prognosis, apparatus and medium
CN117778581A (en) * 2024-01-24 2024-03-29 郑州大学第一附属医院 A human glioma DNA marker and its application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011625A2 (en) * 2002-07-31 2004-02-05 University Of Southern California Polymorphisms for predicting disease and treatment outcome
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
WO2004011625A2 (en) * 2002-07-31 2004-02-05 University Of Southern California Polymorphisms for predicting disease and treatment outcome

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AFFYMETRIX: "GeneChip Human genome U95 Set", DATA SHEET, 2003, XP002504985, Retrieved from the Internet <URL:http://www.affymetrix.com/support/technical/datasheets/hgu95_datasheet.pdf> *
CHEUNG VIVIAN G ET AL: "Mapping determinants of human gene expression by regional and genome-wide association", NATURE (LONDON), vol. 437, no. 7063, October 2005 (2005-10-01), pages 1365 - 1369, XP002504984, ISSN: 0028-0836 *
GLINSKY G V ET AL: "Gene expression profiling predicts clinical outcome of prostate cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 6, 1 March 2004 (2004-03-01), pages 913 - 923, XP002395330, ISSN: 0021-9738 *
GLINSKY GENNADI V ET AL: "Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 115, no. 6, 1 June 2005 (2005-06-01), pages 1503 - 1521, XP002460132, ISSN: 0021-9738 *
IMAI YASUO ET AL: "C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 8, 17 June 2002 (2002-06-17), pages 611 - 616, XP002256816, ISSN: 1535-7163 *
SPIELMAN RICHARD S ET AL: "Common genetic variants account for differences in gene expression among ethnic groups", NATURE GENETICS, vol. 39, no. 2, February 2007 (2007-02-01), pages 226 - 231, XP002504983, ISSN: 1061-4036 *
VARAMBALLY S ET AL: "Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression", CANCER CELL, CELL PRESS, US, vol. 8, no. 5, 14 November 2005 (2005-11-14), pages 393 - 406, XP002395335, ISSN: 1535-6108 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Also Published As

Publication number Publication date
WO2008021483A2 (en) 2008-02-21
CA2660857A1 (en) 2008-02-21
EP2059615A2 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
WO2007114896A3 (en) Prognostic and diagnostic method for cancer therapy
WO2008076447A3 (en) Treatments of therapy-resistant diseases comprising drug combinations
WO2008021483A3 (en) Prognostic and diagnostic method for disease therapy
Labidi et al. Predicting success of endoscopic third ventriculostomy: validation of the ETV Success Score in a mixed population of adult and pediatric patients
EP2788752B1 (en) Method of therapy selection for patients with lung cancer
WO2006085684A3 (en) Method of diagnosing bladder cancer
WO2009103790A3 (en) Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
JP2012500389A5 (en)
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
WO2005024603A3 (en) Methods for detecting, diagnosing and treating human renal cell carcinoma
CA2749817A1 (en) Methods of determining patient response by measurement of her-2 expression
ES2882875T3 (en) Method of prognosis and prediction of breast cancer recurrence, markers used in it and kit of the same
US20200332363A1 (en) Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
WO2012044696A3 (en) Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature
CN106662543A (en) Non-invasive gene mutation detection in lung cancer patients
JP2013532489A (en) Prediction and monitoring of response to cancer treatment based on gene expression profiling
JP2013532489A5 (en)
Sienko et al. Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer
US10233502B2 (en) Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer
MXPA06014175A (en) Diagnosing or predicting the course of breast cancer.
Li et al. Prognostic role of epidermal growth factor-like domain 7 protein expression in laryngeal squamous cell carcinoma
Allingham-Hawkins et al. ERCC1 expression analysis to guide therapy in non-small cell lung cancer
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2012069659A3 (en) Multimarker panel
WO2005113835A3 (en) Kits and methods for indentification, assessment, prevention and therapy of breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836975

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2660857

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007836975

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU